{"id":"71b372acb291","type":"article","url":"https://hartvaat.nl/2018/02/07/abc-doodsscore-bij-af-biomarkergebaseerde-risicoscore-voor-mortaliteit/","title":"ABC-doodsscore bij AF: biomarkergebaseerde risicoscore voor mortaliteit","title_en":"A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehx584","source_url":"https://doi.org/10.1093/eurheartj/ehx584","authors":["Ziad Hijazi","Jonas Oldgren","Johan Lindbäck","John H Alexander","Stuart J Connolly","John W Eikelboom","Michael D Ezekowitz","Claes Held","Elaine M Hylek","Renato D Lopes","Salim Yusuf","Christopher B Granger","Agneta Siegbahn","Lars Wallentin"],"significance":7,"published":"2018-02-07","source_date":"2018-02-07","image":"","kennis":[],"congress":"","summary_en":"This study derived and validated the ABC death risk score (Age, Biomarkers, Clinical history) for mortality prediction in atrial fibrillation, complementing the existing ABC bleeding score and providing a comprehensive biomarker-based risk assessment tool.","created":"2026-07-03T10:27:09Z","updated":"2026-07-03T13:26:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Derivatie en validatie van de ABC-doodsscore (Age, Biomarkers, Clinical history) voor mortaliteitsvoorspelling bij AF. Aanvulling op de ABC-bloedingsscore en ABC-CVA-score.","abstract_original":"AIMS: In atrial fibrillation (AF), mortality remains high despite effective anticoagulation. A model predicting the risk of death in these patients is currently not available. We developed and validated a risk score for death in anticoagulated patients with AF including both clinical information and biomarkers. METHODS AND RESULTS: The new risk score was developed and internally validated in 14 611 patients with AF randomized to apixaban vs. warfarin for a median of 1.9 years. External validation was performed in 8548 patients with AF randomized to dabigatran vs. warfarin for 2.0 years. Biomarker samples were obtained at study entry. Variables significantly contributing to the prediction of all-cause mortality were assessed by Cox-regression. Each variable obtained a weight proportional to the model coefficients. There were 1047 all-cause deaths in the derivation and 594 in the validation cohort. The most important predictors of death were N-terminal pro B-type natriuretic peptide, troponin-T, growth differentiation factor-15, age, and heart failure, and these were included in the ABC (Age, Biomarkers, Clinical history)-death risk score. The score was well-calibrated and yielded higher c-indices than a model based on all clinical variables in both the derivation (0.74 vs. 0.68) and validation cohorts (0.74 vs. 0.67). The reduction in mortality with apixaban was most pronounced in patients with a high ABC-death score. CONCLUSION: A new biomarker-based score for predicting risk of death in anticoagulated AF patients was developed, internally and externally validated, and well-calibrated in two large cohorts. The ABC-death risk score performed well and may contribute to overall risk assessment in AF. CLINICALTRIALS.GOV IDENTIFIER: NCT00412984 and NCT00262600."}